Gilead Sciences Inc (GILD): Today's Featured Drugs Winner

Gilead ( GILD) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day down 0.2%. By the end of trading, Gilead rose $1.06 (2.0%) to $54.38 on light volume. Throughout the day, 7,975,906 shares of Gilead exchanged hands as compared to its average daily volume of 11,790,300 shares. The stock ranged in a price between $53.35-$54.80 after having opened the day at $54.02 as compared to the previous trading day's close of $53.32. Other companies within the Drugs industry that increased today were: Inovio Pharmaceuticals ( INO), up 24.2%, CytRx Corporation ( CYTR), up 20.9%, Prosensa ( RNA), up 19.6% and Redhill Biopharma ( RDHL), up 18.3%.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes human therapeutics for the treatment of life threatening diseases in North America, Europe, and Asia. Gilead has a market cap of $81.3 billion and is part of the health care sector. Shares are up 45.2% year to date as of the close of trading on Monday. Currently there are 19 analysts that rate Gilead a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates Gilead as a buy. The company's strengths can be seen in multiple areas, such as its increase in net income, revenue growth, solid stock price performance, reasonable valuation levels and good cash flow from operations. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook.

On the negative front, Biota Pharmaceuticals ( BOTA), down 70.1%, Mast Therapeutics ( MSTX), down 38.6%, Oramed Pharmaceuticals ( ORMP), down 13.9% and Cormedix ( CRMD), down 11.6% , were all laggards within the drugs industry with Novo Nordisk A/S ( NVO) being today's drugs industry laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

null

More from Markets

Jim Cramer: Schlumberger Predicted the Rise in Oil Prices

Jim Cramer: Schlumberger Predicted the Rise in Oil Prices

Jim Cramer on Zillow's New Business: Buying and Selling Homes

Jim Cramer on Zillow's New Business: Buying and Selling Homes

Jim Cramer on the Markets: It's Natural to Have Some Profit Taking

Jim Cramer on the Markets: It's Natural to Have Some Profit Taking

Video: As Trade Worries Subside, Expect a 'Relief Rally' in Stocks

Video: As Trade Worries Subside, Expect a 'Relief Rally' in Stocks

Stocks Trade Mixed Amid Progress on U.S.-China Trade; Dow Turns Lower

Stocks Trade Mixed Amid Progress on U.S.-China Trade; Dow Turns Lower